Studieoverzicht

Study name: RASolve 308: A Randomized, Double-blind, Phase 3 Study of Pembrolizumab + Pemetrexed + Platinum Chemotherapy With or Without Zoldonrasib (RMC-9805) as First Line Treatment in Patients With Metastatic Non-squamous RAS G12D-Mutated Non-small Cell Lung Cancer

Histology
Tumor stage
NCT Id NCT07777822
Host / recruiting site 1 Rijnstate Enrollment Planned
Therapy line First line (1L)
Design

The purpose of this study is to evaluate the efficacy of an investigational RAS(ON) inhibitor administered in combination with pembrolizumab and platinum-based chemotherapy doublet compared to placebo in combination with pembrolizumab and platinum-based chemotherapy doublet.

Intervention

DRUG: zoldonrasib

oral tablets

DRUG: Placebo

oral tablets

DRUG: pembrolizumab

IV infusion or Subcutaneous injection

DRUG: pemetrexed + cisplatin /carboplatin

IV infusion of either pemetrexed + cisplatin or pemetrexed + carboplatin

Key outcome parameters
  • Progression free survival (PFS)
Key inclusion criteria
  • At least 18 years old and has provided informed consent.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Histologically or cytologically confirmed, previously untreated metastatic non-squamous NSCLC.
  • Known PD-L1 status
  • Documented RAS G12D mutation status.
  • Measurable disease per RECIST v1.1.
  • Adequate organ function (bone marrow, liver, kidney, coagulation, thyroid).
  • Able to take oral medications.
Key exclusion criteria
  • Prior treatment with systemic anticancer therapy in metastatic setting for NSCLC.
  • Prior systemic therapy with any RAS-directed therapy.
  • Untreated (symptomatic or asymptomatic) central nervous system metastatic disease.
  • Any conditions that may affect the ability to take or absorb study drug.
  • Major surgery on or within 28 days prior to randomization.
  • Patient is unable or unwilling to comply with protocol-required study visits or procedures.
  • Additional inclusion and exclusion criteria may apply
Contact information